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INTRODUCTION 
Malaria is the world’s most important parasitic infection 1. 
At present about 100 countries or territories in the world 
are considered malarious, almost half of which are in 
Africa, south of the Sahara 
2
. The incidence of malaria 
worldwide is estimated to the 300-500 million clinical 
cases each year- majority caused by Plasmodium 
falciparum. Malaria is thought to kill between 1.1 & 2.7 
million people worldwide each year 
2
 and kills a child 
somewhere in the world every 30 seconds 
3
.  
The treatment of Plasmodium falciparum malaria has been 
changed over the past two decades in response to declining 
sensitivity of Plasmodium falciparum to conventional 
antimalarial drugs 
1
. The parasite remains fully sensitive to 
chloroquine only in Central America, north of the Panama 
Canal, in Haiti, Egypt and in scattered pockets of Asia and 
South America 
4
. Southeast Asia, including India, lie in the 
zone of chloroquine resistance 
2, 4
. However, world maps 
that depict countries as having or not having drug resistant 
malaria are potentially misleading, as there is great 
heterogeneity within countries and across boundaries. 
Local knowledge is therefore of paramount importance 
4
.  
The treatment of malaria depends on patient’s age, the 
severity of infection, the likely pattern of susceptibility to 
antimalarial drugs, cost and availability of such drugs. For 
this reason recommendations vary according to geographic 
region and should be under constant review 
1
. Though 
chloroquine is still the mainstay of antimalarial treatment, 
the emergence of Plasmodium falciparum resistant to this 
drug has challenged control efforts and has been linked to 
increased mortality 
5
. Krishna 
6, stated that “assume that 
Plasmodium falciparum is chloroquine resistant unless in 
an area with known chloroquine sensitivity”. White and 
Breman 
7, have opined “in areas where Plasmodium 
falciparum is still sensitive, chloroquine is used as the 
second drug”. Todd et al. 8, also agreed with this view and 
recommended that “Plasmodium falciparum is now 
resistant to chloroquine almost worldwide, notable in Asia 
and Africa, so quinine is the drug of choice as 
dihydrochloride or sulfate”. 
Quinine is a good alternative to chloroquine but it has 
several limitations 
9
. It is used in combination with 
tetracyclines, such as doxycycline, in areas where quine 
resistance is also documented or possible. The artemisinin 
derivatives are better tolerated alternatives to quinine. 
Artemisinin and its derivatives are sesquiterpene lactone 
peroxides derived from the leaves the sweet wormwood 
(Artemisia annua) and related plants 
4
. It has been used 
ABSTRACT 
Background: The treatment of falciparum malaria has changed over the past two decades in response to declining sensitivity 
of P. falciparum to conventional antimalarial drugs. The treatment depends on patient’s age, the severity of infection, the likely 
pattern of susceptibility to antimalarial drugs, cost and availability of such drugs. For this reason recommendations vary 
according to geographic region and should be under constant review. In this perspective we conducted the present study in this 
part of the world, Burdwan Medical College, West Bengal, India, where no such study conducted before.  Objective: The 
objective of our study was to evaluate the efficacy of Artemether and Doxycycline combination against Quinine and 
Doxycycline combination in acute uncomplicated falciparum malaria as the primary objective. Our secondary objective was to 
evaluate the safety profile of the two combination regimens in terms of the adverse event profiles.  Materials and Methods: 
In this study total 84 patients were randomly recruited after fulfillment of the inclusion criteria, from the Medicine inpatients 
Department of Burdwan Medical College& Hospital, West Bengal, during the period of May 2007 to December 2010. All the 
eligible patients suffering from uncomplicated falciparum malaria were randomly allocated to two groups. The 1st group was 
receiving Quinine sulfate 10 mg salt per kg body weight 8 hourly for 7 days plus Doxycycline hyclate 100 mg 12 hourly for 7 
days. And the 2nd group was receiving Artemether 80 mg every 24 hours for 5 days with an additional 80 mg dose 12 hours 
after the first dose, plus Doxycycline hyclate 100 mg ( of Doxycycline) 12 hourly for 7 days. They were discharged after 7 
days and advised for follow up on days 14 and 28. Efficacy was measured by the two variables: [1] Primary efficacy variables, 
included as (i) Fever Clearance Time and (ii) Parasite Clearance Time and the [2] Secondary efficacy variables, included as (i) 
Cure Rate and (ii) Relapse Rate.   Results: In our study, cure rate was 84.21% and 100% of the 1st group & 2nd group 
respectively, with the later was significantly better than the 1st one (p= 0.014). Fever Clearance time of the 2nd group was 
significantly shorter (p= 0.001) than that of the 1st one and the Parasite Clearance Time of the 2nd group was also significantly 
shorter (p= 0.002) than that of the 1st one. Though the frequency of nausea and vomiting was slightly higher in the 2nd group, 
but not statistically significant (p= 0.11). Conclusion: In our study, in this institution combination of Artemether plus 
Doxycycline was highly effective than the combination of Quinine plus Doxycycline in the uncomplicated falciparum malaria 
and was well tolerated.  
Key Words: Malaria, Plasmodium falciparum, Uncomplicated, Artemether, Doxycycline 
 
 
Bandyopadhyay et al                               Journal of Drug Delivery & Therapeutics; 2013, 3(4), 247-253    248 
2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
traditionally in Chinese medicine as ‘qinghaosu’- 
pronounced ‘ching-how-soo’ 10. Three derivatives are 
currently available- Artesunate, a water soluble form, and 
the lipid soluble Artemether and Arteether 
11
. Artemisinin 
derivatives kill all stages of malaria parasites, including 
‘young rings’ by interacting with heme to produce carbon-
centered free radicals that alkylate proteins and membranes 
11
. They have potent antimalarial activity, attractive safety 
profiles and are yet to be associated with significant 
resistance 
5
. Qinghaosu and its derivatives have been 
studied extensively in China and Southeast Asia during the 
last 10 years. The effectiveness of these drugs in clearing 
parasites has been thoroughly documented 
12
.  
The essence of our study is to search for a better 
combination regimen in comparison to the older quinine-
doxycycline duo. There is growing belief among 
malariologists that to prevent resistance, falciparum 
malaria should no longer be treated with single drugs in 
endemic areas, the same strategy that has been applied to 
the treatment of other infectious diseases of major global 
public health significance such as tuberculosis and 
HIV/AIDS. This strategy is based upon simultaneous use 
of two or more drugs with different modes of action 
7
. The 
basic tenet is that the probability of resistance developing 
simultaneously to two chemotherapeutic agents with 
independent mechanism of action is extremely low, of the 
order of once in 10
12
 treatments. This frequency is the 
product of the probabilities of the acquisition of a resistant 
mutation to each drug multiplied by the number of 
parasites in a typical infection 
3
. Combinations also 
prevent recrudescence or relapse of symptoms.  
Combination of quinine with doxycycline is time-tested 
and retains at least 85% effectiveness nearly everywhere 
1
. 
As quinine has limitations and artemisinin compounds are 
good alternatives, several drug combinations with 
artemisinin have been and are being evaluated till date. For 
example, artesunate plus amodiaquine, artemisinin 
derivative with mefloquine, artemether with lumefantrine 
and so on. Assessment of these and other effective and 
well-tolerated combination regimens containing 
artemisinin compounds is needed in other geographical 
areas 
5
. In this scenario we conducted our study in this 
geographical area, Burdwan Medical College& Hospital, 
West Bengal, India.  For our study we had chosen 
artemether in combination with doxycycline and compared 
to the standard quinine plus doxycycline regimens.  All 
drugs were administered by the oral route.      
MATERIALS AND METHODS  
Study duration: For the individual patients, the study 
duration was 28 days including follow-up study visits. The 
entire study was completed from May 2007 to December 
2010.  
Ethical consideration: This study was conducted in 
accordance with the principles enunciated in the 
Declaration of Helsinki for Biomedical Research involving 
Human Subjects. Also every effort was made to adhere to 
the spirit of the Good Clinical Practice guidelines of the 
Government of India 
13
. Written informed consent was 
taken from each of the individuals. The protocol and the 
patients’ informed consent form was approved by the 
Institutional Ethics Committee.  
Sample size: Total 84 patients, suffering from 
uncomplicated falciparum malaria, were recruited from the 
Medicine inpatients Department of Burdwan Medical 
College,West Bengal, after fulfillment of the inclusion& 
exclusion criteria.  
Inclusion criteria:  
        a) Subject aged between 15 to 65 years.  
        b) Subject weighing at least 45 kg. 
         c) History of fever (≥ 100 0F) within the past 48 
hours.  
        d) Screening of peripheral blood smears showing 
presence of Plasmodium falciparum.                           
        e) Willing to provide written informed consent. 
Exclusion criteria:  
a) Female subject who is pregnant or breast feeding. 
b) Estimated extent of parasitaemia > 105 /μL. 
c) Screening of peripheral blood smears showing 
presence of mixed malarial infection i.e. Plasmodium 
vivax + Plasmodium falciparum.  
d) Subject having evidence of  
 Impaired consciousness. 
 Severe anemia (Hb < 5 g/ dL). 
 Jaundice or compromised liver function (ALT or 
AST > 3 times upper limit of normal. 
 Respiratory distress. 
 Hamaturia. 
 Hypoglycemia (Blood glucose < 70 mg/ dL).   
e) Subject having history of  
 Optic neuritis. 
 Significant tinnitus. 
 Severe glucose-6-phosphate dehydrogenase 
(G6PD) deficiency. 
 Severe cardiac dysrhythmias. 
f) History of use of any antimalarial for the current 
febrile episode or within the past 1 month. 
g) History of use of any medication that may 
influence the activity of antimalarial drugs, e.g. folate, 
azithromycin, dapsone, etc. , within the past 7 days or 
longer depending upon the nature of the drug.  
h) History of Blood transfusion within the past 1 
month.  
i) History of allergy (hypersensitivity) to 
artemether, quinine, doxycycline or closely related drugs.  
j) Any concomitant serious disorder of the kidney, 
heart, lungs or other vital organs. 
k) Unwilling to remain hospitalized for at least 7 
days or to return for follow up at the stipulated days on 
14
th
 day and 28
th
 days.  
l) History of alcohol or substance abuse. 
Study Methodology:  
a) Study design: Our study was post registration 
(Phase IV), prospective, open, randomized, controlled 
study with the two parallel treatment groups.   
b) Study time schedule: All the recruited subjects 
were admitted to the medicine inpatients departments and 
was studied as in-patient for 7 days. Thereafter they were 
discharged & was advised to come on the day 14 and 28
th
 
days for follow up study.  
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c) Baseline assessment: At presentation every 
patient was screened for presence of a history of fever 
within the past 48 hours and the presence of Plasmodium 
falciparum in the peripheral blood smear. A serological 
test for Plasmodium falciparum HRP-2 antigen was also 
carried out.  Blood was also collected for  baseline 
laboratory test including complete hemogram & blood 
biochemistry.  
d) Study evaluation: Plasmodium falciparum 
infection was diagnosed first. Then the response to study 
drugs was evaluated by Primary & secondary efficacy 
variables. Diagnosis of falciparum malaria was based on 
blood smear test 
5, 12
 and detection of Plasmodium 
falciparum HRP-2 antigen with a rapid dipstick antigen 
capture assay 
14
. 
Blood Smear Test: Both thick & thin films were prepared 
from finger prick blood samples and stained with 2% 
Giemsa stain for 30 minutes. All smears being examined at 
the magnification of 1000. Blood smear was collected 
every 12 hours interval after commencement of treatment 
until two consecutive examinations were negative. From 
blood smear quantization of the parasitemia was done as 
follows. Total RBC or WBC was counted first. Then the 
number of asexual parasites per 1000 RBC in a thin film or 
parasites per 200 WBC in a thick film counted. Parasite 
density was calculated by multiplying both the numbers 
and expressed as parasites per μL. Blood film considered 
as negative when no parasites were seen in 200 oil-
immersion fields in a thick blood film 
5, 12
. 
Detection of Plasmodium falciparum HRP-2 antigen by 
rapid dipstick antigen capture assay: Antibody capture 
of circulating plasmodium specific antigens –a technique 
proposed for rapid diagnosis of malaria 
14
. The 
Plasmodium falciparum histidine rich protein-2 (PfHRP-
2)- a water soluble antigen released by blood stages of the 
parasite- a target for antigen capture assay. Fifty μL blood 
placed in a labeled polypropylene tube and three drops 
(about 100 μL) of a RBC lysing agent added. After gently 
agitating the tubes, specimens were ready for testing by the 
antigen capture assay. Assay test sticks were made of 
cellulose fiber and contain an immobilized IgG1 
monoclonal antibody directed against the synthetic peptide 
(AHH [AHHAAD] 2) from PfHRP2. Test sticks were 
packaged with desiccant in foil pouches and kept 
unrefrigerated. One drop of a lysed blood specimen 
dispensed into one well of a ten-specimen test-stick holder 
platform. The end of a test-stick was placed in the drop of 
lysed blood. The drop of blood was absorbed by the test-
stick along its entire length, a process required 2- 10 
minutes depending on the specimen.PfHRP2 antigen 
detector reagent (containing polyclonal antibodies against 
PfHRP2 that conjugated to liposomes containing pink dye) 
was then added to every specimen well. After the antigen 
detector reagent was absorbed by the test-stick, a wash 
reagent was added and absorbed. The result was read 
immediately. A positive test result (PfHRP2) showed as a 
thin, solid, pink band that appeared on the dipstick.  
Different field studies showed that when Plasmodium 
falciparum asexual parasitemia is greater than 60 parasites 
per μL, the dipstick test is 96.5- 100% sensitive 2. At lower 
level of parasitemia the sensitivity decreases; however at 
11-60 parasites per μL of blood, the assay still detects 70-
80% of infection and at 10 parasites per μL of blood or 
less, the assay detects 11-67% of infection 
13
. Since most 
individuals with symptomatic Plasmodium falciparum 
infection have greater than 60 parasites per μL of blood, 
the dipstick assay will be of particular use in rapid 
diagnosis of febrile patients and in epidemiologic field 
studies 
12
. Furthermore because inexperienced 
microscopists often have difficulty in detecting less than 
60 parasites per μL of blood, assessment of comparative 
sensitivity of blood films and dipstick assay among such 
technicians may indicate that dipstick has greater 
sensitivity than blood smear. Further the test is easy to 
perform, does not require electricity or elaborate 
equipment. Only a small amount of unprocessed whole 
blood is required. Analysis of a single specimen can be 
completed within 20 minutes. Usually PfHRP2 antigen is 
not detectable in blood 6 days after initiation of current 
chemotherapy suggesting that circulating antigen rarely 
lead to false positive test 
14
. However, one problem with 
PfHRP-2 based tests is the persistence of HRP-2 antigen 
after effective treatment, possibly making these tests less 
suitable for identifying treatment failure 
2
. Hence this test 
was not used during follow up period in this study.  
Study treatment: All the eligible subjects were randomly 
allocated in to two treatment groups. [A] 1
st
 group total 
patients were 43. They received  Quinine sulfate 10 mg 
( of the salt ) per kg body weight 8 hourly for 7 days 
plus Doxycycline hyclate 100mg ( of doxycycline ) 12 
hourly for 7 days.   
[B] In the 2
nd
 group total patients were 41. They 
received Artemether 80 mg every 24 hours for 5 days 
with an additional 80 mg dose 12 hours after the first 
dose plus Doxycycline hyclate 100mg ( of doxycycline ) 
12 hourly for 7 days.    
All the drugs were administered by oral route. The 
following brands were used.  
Artemether – Cap Larither [Manufacture: M/s IPCA 
Laboratories Ltd. Mumbai]. Each capsule contained 40 mg 
of artemether. Quinine was used as Tab Cinkona 
[Manufacture: M/s IPCA Laboratories Ltd. Mumbai]. 
Doxycycline was used as Cap Doxy-1 [Manufacture: M/s 
USV Limited, Mumbai].Each capsule containing 100 mg 
of doxycycline as hyclate. 
Assessment of the Efficacy of the Study Drugs: By the 
two variables.  
a) Primary Efficacy Variables: (i) Fever 
Clearance Time 
14
: Defined as the time from the start of 
the treatment until the temperature measured in the mouth 
fall to < 99 
0
F ( to the nearest 6 hours after start of 
treatment ) and subsequent sublingual temperature 
remained  < 100 
0
F for at least 24 hours. (ii) Parasite 
Clearance Time 
14
: Defined as the time from the start of 
the treatment until the first time the slide became negative 
( to the nearest 12 hours after start of treatment), with 
subsequent blood smears remaining negative until the last 
study assessment on the day 28.   
b) Secondary Efficacy Variables: (i) Cure Rate: 
Defined as the proportion of the patients who responded to 
treatment and remained symptomatically relieved (i.e. no 
fever) as well as free from parasitemia till the 28
th
 day of 
follow up. (ii) Relapse rate: Defined as the proportion of 
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the patients who responded to treatment (fever clearance 
and parasite clearance were achieved) but showed 
recurrence of symptoms (i.e. fever) and or parasitemia 
before the end-of-trial visit on day 28 following 
commencement of study medication.  
Data Analysis:  All the collected data were analyzed using 
the Statistical Package for the Social Science (SPSS) ver-
16 in Windows-7 and Microsoft Excel. Efficacy data 
evaluated by an intention-to-treat analysis for subjects who 
had taken study medication for at least 48 hours. 
Parametric data compared by the Student’s t test, while 
non-parametric numerical data compared by the Mann-
Whitney U test, with p < 0.05 was the cut-off level for 
statistical significance. Categorical data compared by χ2 
test and also by the Fisher’s exact test.  
RESULTS AND ANALYSIS  
During the May 2007 to December 2010, total 84 patients 
were enrolled in this study. Out of that 43 patients were 
allocated randomly to the 1
st
 group, i.e. quinine plus 
doxycycline group. In that group 90.697% & 9.303% of 
patients were male and female respectively. Age range of 
that group was 15 to 60 years. All the patients were 
suffering from fever. Duration of fever before admission 
was 4.3 ± 2.89 (Mean ± SD) days and highest fever before 
treatment was 38.7 ± 0.69          (Mean ± SD) 
0
C. In the 2
nd
 
group 41 patients were allocated randomly i.e. they were 
belonged to artemether plus doxycycline group. In the 2
nd
 
group 87.804% & 12.195% of patients were male and 
female respectively. Average age was 23.6 ± 7.01 (Mean ± 
SD) years. All were suffering from fever. Average 
duration of fever was 4.5 ± 3.59 (Mean ± SD) and highest 
temperature before treatment was 38.8 ± 0.68 (Mean ± SD) 
0
C. The details of the Clinical and Laboratory 
characteristic of the both two groups of patients, before 
treatment started, are shown in the Table No. 1. & Table 
No. 2.  
 
Table No. 1: Showing the baseline Clinical Characteristics of both the two groups of the patients: 
Table No. 1  1
st
 Group: Quinine plus Doxycycline 
( n = 43) 
2
nd
 Group: Artemether plus 
Doxycycline ( n= 41)  
Sex:     Male  39 (90.697%) 36 (87.804%) 
            Female  4 (9.303%) 5 (12.195%)  
Age:    Mean ± SD  23 ± 6.9 years 23.6 ± 7.01 years 
            Range  15-60 years  15-65 years 
Weight: Mean ± SD 49.5 ± 5.60 kg 51 ± 5.89 kg 
Fever: Duration before 
admission(Mean ± SD) 
4.3 ± 2.89 days 4.5 ± 3.59 days 
 Highest temperature before 
treatment (Mean ± SD)          
38.7 ± 0.69 
0
C 38.8 ± 0.68 
0
C 
No. of Patients                  With       
Splenomegaly 
14 (32.558%) 5 (12.195%)  
With        Hepatomegaly 8 (18.604%) 9 (21.951%) 
With First Malarial Attack 8 (18.604%) 7 (17.073%) 
Mean Parasite count  22860 per μL 25820 per μL 
Range of Parasite count 412-151441 per μL 191-185410 per μL 
 
Table No.2: Showing the baseline Laboratory Characteristics of both the two groups of the patients 
 Table No.2:     
 Laboratory data  (Mean ±SD) 
1
st
 Group: Quinine plus Doxycycline 
( n = 43) 
2
nd
 Group: Artemether plus 
Doxycycline(n= 41) 
Packed Cell Volume (%) 34.9 ± 6.8 36.3 ± 6.2 
WBC Count (per μL) 4853 ± 1419 5530 ± 4329 
Platelet count (10
3/μL) 1661 ± 855 1593 ± 891 
ESR (ml/hr) 42.1 ± 30.89 43.6 ± 24.53 
Blood Urea (mmol/L) 6.12 ± 2.01 6.89 ± 4.13 
Serum Creatinine (μmol/L)  102 ± 10 103 ± 17 
Total Bilirubin(μmol/L) 22.1 ± 19.19 24.13 ± 21.3 
Serum AST(μmol/L) 41.39 ± 22.5 51.1 ± 22.5 
Serum ALT(μmol/L) 39.18 ± 22.5 41.13 ± 28.5 
Serum Albumin (mg/L) 38 ± 3.8 38.5 ± 2.9 
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After treatment started, fever clearance time was 
significantly shorter in the 2
nd
 group (artemether plus 
doxycycline) than that of the 1
st
 group (p = 0.001). Similar 
significant faster response of parasite clearance time of the 
2
nd
 group (p= 0.002). Though in the two groups, the 
parasite count was reduced by 80% within the 60 hours, 
but the mean Parasite clearance time of the 1
st
 group was 
61.09 ± 28.06 hours (mean ±SD), while that of the 2
nd
 
group was 36.49 ± 28.19 hours (mean ±SD). Fever 
clearance time of the 1
st
 group was 68.69 ± 38.06 hours 
(mean ± SD) and that of the 2
nd
 group was 35.47 ± 22.19 
hours (mean ± SD). In this study 38 patients of the 1
st
 
group completed the last 28
th
 day follow-up study, while 
39 patients of the 2
nd
 group completed the same. Cure rate 
of the 1
st
 group was 84.21%, while that of the 2
nd
 group 
was 100%.  
The details Therapeutic Responses of both the groups are shown in the Table No. 3. 
Table No. 3: Therapeutic Efficacy 
Measurements: 
1
st
 Group: Quinine Plus 
Doxycycline (n= 43) 
2
nd
 Group: Artemether Plus 
Doxycycline (n=41) 
No. of Patients with 28 days follow-up 38 39 
No. (%) Cured in 28 days 32 (84.21%) 39 (100%) 
Fever Clearance Time (hrs) 
Mean ± SD 
68.69 ± 38.06 35.47 ± 22.19 
Range (hrs) 6-149 4-129 
ParasiteClearance Time(hrs) 
Mean± SD 
61.09 ± 28.06 36.49 ± 28.19 
Range (hrs) 18-90 16-69 
 
 
Figure 2: Time of the mean parasite clearance is distributed 
The nature and the severity of the adverse drug reactions 
were not significantly different in both the two groups. 
Headache, dizziness had been noticed in only 13 & 8 
patients of the 2
nd
 group, while diarrhea was most common 
among the 44.186% of the patients of the 1
st
 group. 7 
artemether + doxycycline, treated patients reported nausea 
and 10 patients reported vomiting after 48 hours of 
treatment, but no additional treatment was required. No 
patients were discontinued from the study drug treatment 
due to adverse drug reaction.  
Serial blood examination showed that packed cell volume 
gradually increased after treatment in both the groups. 
Absolute neutrophil counts were low before treatment in 
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Figure No. 1: Showing Some of the Baseline Clinical Characteristic of Both the Two Groups of 
Patients  
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Figure No.2: Showing the Mean Parasite Clearance Curve (p= 0.002) 
Quinine Plus Doxycycline 
Artemether Plus Doxycycline 
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both groups, but gradually increased to normal values within 3-4 weeks of treatments. 
 
The details adverse drug reaction profiles of the patients of both the two groups are shown in the Table No. 4. 
  
    
                                       
DISCUSSION 
Malaria is a protozoan disease transmitted by the bite of 
infected Anopheles mosquitoes. The most important of the 
parasitic diseases of humans, it is transmitted in 108 
countries containing 3 billion people and causes nearly 1 
million deaths each year 
15
. Malaria has been eliminated 
from the United States, Canada, Europe, and Russia; in the 
late twentieth and early twenty-first centuries, however, its 
prevalence rose in many parts of the tropics 
16
. Malaria can 
behave like an epidemic disease in some areas, particularly 
those with unstable malaria, such as northern India (the 
state of Rajasthan), Sri Lanka, Iraq, and Turkey, the horn 
of Africa, Rwanda, Burundi, southern Africa, Madagascar, 
and central Asia 
17
.  
Malaria is a very common cause of fever in tropical 
countries. William Osler 
7
 stated that “Humanity has but 
three great enemies. Fever, famine and war, of these by far 
the greatest, by far the terrible, is fever”. The treatment of 
falciparum malaria has changed radically in recent years. 
In all endemic areas, the World Health Organization 
(WHO) 
18
 now recommends artemisinin-based 
combinations as first-line treatment for uncomplicated 
falciparum malaria. These rapidly and reliably effective 
drugs are sometimes unavailable in temperate countries, 
where treatment recommendations are limited by the 
registered available drugs. Fake or substandard 
antimalarials are commonly sold in many Asian and 
African countries. Thus, careful attention is required at the 
time of purchase and later, especially when the patient fails 
to respond as expected 
18
. Current Artemisinin based 
combination  regimens that are well tolerated in adults and 
children >5 kg include artemether-lumefantrine, 
artesunate-mefloquine, artesunate-amodiaquine, 
artesunate-sulfoxadine-pyrimethamine, and 
dihydroartemisinin-piperaquine & pyronaridine 
19
. 
But when we started our study, in the early 2007, we 
designed to use artemether plus doxycycline combination, 
by following the as usual strategy of the treatment of 
global public health importance, likes treatment of 
tuberculosis, HIV/AIDS, etc. 
 White NJ 
20
 stated that as a class, the artemisinins are very 
potent and fast-acting antimalarials, inducing more rapid 
parasite clearance and fever resolution than any other 
currently licensed antimalarial drug. They are particularly 
well suited for the treatment of P. falciparum malaria. . 
Artemisinins cause a significant reduction of the parasite 
burden, with a four-log10 reduction in the parasite 
population for each 48-hour cycle of intra erythrocytic 
invasion, replication, and regress. As such, only three to 
four cycles (6-8 days) of treatment are required to remove 
all the parasites from the blood. Additionally, artemisinins 
possess some gametocytocidal activity, leading to a 
decrease in malarial parasite transmission. Artemisinins act 
early in the asexual parasite development cycle, whereas 
Headache  
Abdominal 
Pain 
Diarrhoea Nausea Vomiting Dizziness 
Quinine Plus Doxycycline 34.88% 2.32% 44.19% 13.95% 16.27% 25.58% 
Artemether Plus Doxycycline 31.70% 4.88% 4.88% 17.07% 24.39% 19.51% 
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Figure No. 3: Showing the distribution of Adverse Drug Reaction profile  of the 
patients of both the two groups  
Table No. 4:Adverse Drug Reaction 
Profile 
1
st
 Group: Quinine Plus Doxycycline 
(n= 43) 
2
nd
 Group: Artemether Plus 
Doxycycline (n=41) 
Headache  15 (34.88%) 13 (31.70% 
Abdominal Pain 1 (2.32%)  2 (4.875%) 
Diarrhea   19 (44.186%) 2 (4.875%) 
Nausea 6 (13.953%) 7 (17.07%) 
Vomiting 7 (16.27%) 10 (24.39% 
Dizziness 11 (25.58%) 8 (19.51%) 
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quinine acts at the late stage 
21
. Probably due to that reason 
in our study, artemether containing combination had 
shorter parasite clearance time & fever clearance time and 
no recrudescence among the patients of the 2
nd
 group, it 
was 100% cure but in the 1
st
 group it was at the rate of 
84.21%. 
In our comparative therapeutic trial of 43 months duration 
in total 84 patients with uncomplicated falciparum malaria, 
a combination of artemether plus doxycycline resulted in 
radical cures, with some self-limiting side effects in a few 
patients in comparison with quinine plus doxycycline 
group.  
Different studies 
22, 23, 24, 25
 conducted in various parts of 
the world with the different combination of artemisinin 
based compound on the falciparum malaria producing 
varying results in their geographic area, but our study in 
this part of the world tally with some of the results.  
CONCLUSION 
Though there were limitations in this study especially 
involving small number of patients in only one institution, 
but the present study showed that artemether plus 
doxycycline combination was a safer and better alternative 
than the quinine plus doxycycline combination. 
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